ArticleFrontiers in medicine2022
The Significance of Crescents on the Clinical Features and Outcomes of Primary Immunoglobin A Nephropathy.
Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 4 syntheses or guidelines pooled it, 11 citations in OpenAlex.
- Risk Factors of Disease Progression in IgA Nephropathy: A Systematic Review and Meta-Analysis.Immunity, inflammation and disease · 2026Pooled it
- Association between different proportions of crescents and adverse renal outcomes in immunoglobulin a nephropathy: a systematic review and meta-analysis.Renal failure · 2025Pooled it
- Predictive role of Oxford Classification for prognosis in children with IgA nephropathy: a systematic review and meta-analysis.Renal failure · 2024Pooled it
- Association between different proportions of crescents and the progression of IgA nephropathy (IgAN): a systematic review and meta-analysis.BMC nephrology · 2024Pooled it
- Impact of crescents on the immunosuppression treatment of IgA nephropathy.Renal failure · 2025Article
- Pilot Study of sC5b-9 and Bb Fragment Plasma Levels in Crescentic Immunoglobulin A Nephropathy.Kidney international reports · 2024Article
- The Clinicopathological Correlation and Outcome of Glomerulonephritis With Crescent: A Single-Center Study.Cureus · 2024Article
- Evaluating the State of Glomerular Disease by Analyzing Urinary Sediments: mRNA Levels and Immunofluorescence Staining for Various Markers.International journal of molecular sciences · 2024Article
- Microscopic hematuria as a risk factor for IgAN progression: considering this biomarker in selecting and monitoring patients.Clinical kidney journal · 2023Review
- Crescents proportions above 10% are associated with unfavorable kidney outcomes in IgA nephropathy patients with partial crescent formation.Renal failure · 2023Article
- A novel clinical-radiomic nomogram for the crescent status in IgA nephropathy.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: It is still controversial whether the proportion of crescents below 50% can be an independent predictive risk factor for poor prognosis in IgAN patients. We reported the significance of different proportions of crescents on the clinical features and the cut-off value of crescents in predicting the occurrence of end-stage kidney disease (ESKD) in patients with IgAN. Methods: We retrospectively analyzed biopsy-proven primary IgAN patients in Sichuan Provincial People's Hospital from 2007 to 2019. The patients were divided into 5 groups on the basis of crescent proportion as follows: 0 ( Results: A total of 1242 eligible patients with biopsy-proven IgAN were recorded in the database, compared with the non-crescent group, patients in the crescent group had lower levels of hemoglobin (Hb) and albumin (Alb), higher levels of blood urea nitrogen (BUN), 24h urinary protein and hematuria, a higher proportion of mesangial hypercellularity (M1), endocapillary hypercellularity (E1), segmental glomerulosclerosis (S1), and tubular atrophy/interstitial fibrosis (T1/T2) ( Conclusion: IgAN patients with crescents had more severe clinicopathological features and poorer prognosis. Crescents ≥50% was an independent risk factor for the progression of ESKD and crescents ≥25% was an independent risk factor for ≥50% reduction in eGFR or ESKD in treated and untreated IgAN patients. Crescents ≥43.7% was an independent risk factor for ESKD in those with immunosuppressants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.